ETC-1002 738606-46-7 GlpBio
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Product Data Sheet
Product Name:ETC-1002
Cat. No.:GC11827
Chemical Properties
Cas No.738606-46-7
Chemical
Name
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
Canonical
SMILES
OC(C(C)(C)CCCCCC(O)CCCCCC(C)(C)C(O)=O)=O
Formula C19H36O5M.Wt344.49 Solubility≥97.6mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.
Structure
Background
ETC-1002 is an oral ACL inhibitor (IC50= 29 μM) and AMPK activator.
In vitro, ETC-1002 increased levels of AMP-activated protein kinase (AMPK) phosphorylation, reduced activity of MAP kinases and decreased production of proinflammatory cytokines and chemokines. These effects on soluble mediators
Product Data Sheet
of inflammation can be significantly abrogated by LKB1 siRNAs, indicating that ETC-1002 activates AMPK and exerts its anti-inflammatory effects via an LKB1-dependent mechanism. [1]
In vivo, ETC-1002 suppressed thioglycollate-induced homing of leukocytes into mouse peritoneal cavity. ETC-1002 restored adipose AMPK activity, reduced JNK phosphorylation, and diminished expression of macrophage-specific marker 4F/80 in a mouse model of diet-induced obesity. [1]
In clinical trial, ETC-1002 reduced low-density lipoprotein-cholesterol (LDL-C) and other lipids and improved in high-sensitivity C-reactive protein in patients with type 2 diabetes mellitus and hypercholesterolemia without worsening glycemic control. ETC-1002 was low toxicity in this population. [2]
References:
1. Filippov S1, Pinkosky SL, Lister RJ et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54(8):2095-108.
2. Gutierrez MJ1, Rosenberg NL, Macdougall DE et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-8
3.